Epitope mapping of BP230 leading to a novel enzyme-linked immunosorbent assay for autoantibodies in bullous pemphigoid

British Journal of Dermatology

Volumn 166, Issue 5, 2012, Pages 964-970

  Blocker I M ^a   Dahnrich C ^a   Probst, C ^a   Komorowski, L ^a   Saschenbrecker, S ^a   Schlumberger, W ^a   Stocker W ^a   Zillikens, D ^b   Schmidt, E ^b  

^a Institute of Experimental Immunology   (Germany)

^b UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BULLOUS PEMPHIGOID ANTIGEN 1;

ARTICLE; BLOOD DONOR; BULLOUS PEMPHIGOID; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; ESCHERICHIA COLI; FAR WESTERN BLOTTING; HUMAN; PEMPHIGOID GESTATIONIS; PEMPHIGUS VULGARIS; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; SYSTEMIC LUPUS ERYTHEMATOSUS;

AUTOANTIBODIES; BLOTTING, WESTERN; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; HUMANS; MEMBRANE GLYCOPROTEINS; PEMPHIGOID, BULLOUS; RECOMBINANT PROTEINS; ROC CURVE;

EID: 84860321636     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.10820.x     Document Type: Article

References (42)

1. Langan SM, Smeeth L, Hubbard R, et al. Bullous pemphigoid and pemphigus vulgaris-incidence and mortality in the UK: population based cohort study. BMJ 2008; 337: 160-3. (Pubitemid 352039867)
2. Bertram F, Brocker EB, Zillikens D, et al. Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. J Dtsch Dermatol Ges 2009; 7: 434-40.
3. Marazza G, Pham HC, Scharer L, et al. Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study. Br J Dermatol 2009; 161: 861-8.
4. Schmidt E, Zillikens D,. The diagnosis and treatment of autoimmune blistering skin diseases. Dtsch Arztebl Int 2011; 108: 399-405, I-III.
5. Stanley JR, Hawley-Nelson P, Yuspa SH, et al. Characterization of bullous pemphigoid antigen: a unique basement membrane protein of stratified squamous epithelia. Cell 1981; 24: 897-903. (Pubitemid 11071328)
6. Stanley JR, Tanaka T, Mueller S, et al. Isolation of complementary DNA for bullous pemphigoid antigen by use of patients' autoantibodies. J Clin Invest 1988; 82: 1864-70. (Pubitemid 19054931)
7. Diaz LA, Ratrie H III, Saunders WS, et al. Isolation of a human epidermal cDNA corresponding to the 180-kD autoantigen recognized by bullous pemphigoid and herpes gestationis sera. Immunolocalization of this protein to the hemidesmosome. J Clin Invest 1990; 86: 1088-94. (Pubitemid 20370412)
8. Giudice GJ, Emery DJ, Diaz LA,. Cloning and primary structural analysis of the bullous pemphigoid autoantigen BP180. J Invest Dermatol 1992; 99: 243-50.
9. Giudice GJ, Emery DJ, Zelickson BD, et al. Bullous pemphigoid and herpes gestationis autoantibodies recognize a common non-collagenous site on the BP180 ectodomain. J Immunol 1993; 151: 5742-50. (Pubitemid 23332383)
10. Zillikens D, Rose PA, Balding SD, et al. Tight clustering of extracellular BP180 epitopes recognized by bullous pemphigoid autoantibodies. J Invest Dermatol 1997; 109: 573-9. (Pubitemid 27433604)
11. Schmidt E, Reimer S, Kruse N, et al. Autoantibodies to BP180 associated with bullous pemphigoid release interleukin-6 and interleukin-8 from cultured human keratinocytes. J Invest Dermatol 2000; 115: 842-8.
12. Sitaru C, Schmidt E, Petermann S, et al. Autoantibodies to bullous pemphigoid antigen 180 induce dermal-epidermal separation in cryosections of human skin. J Invest Dermatol 2002; 118: 664-71. (Pubitemid 34309987)
13. Nishie W, Sawamura D, Goto M, et al. Humanization of autoantigen. Nat Med 2007; 13: 378-83. (Pubitemid 46376680)
14. Li Q, Ujiie H, Shibaki A, et al. Human IgG1 monoclonal antibody against human collagen 17 noncollagenous 16A domain induces blisters via complement activation in experimental bullous pemphigoid model. J Immunol 2010; 185: 7746-55.
15. Iwata H, Kamio N, Aoyama Y, et al. IgG from patients with bullous pemphigoid depletes cultured keratinocytes of the 180-kDa bullous pemphigoid antigen (type XVII collagen) and weakens cell attachment. J Invest Dermatol 2009; 129: 919-26.
16. Schmidt E, Obe K, Brocker EB, et al. Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol 2000; 136: 174-8. (Pubitemid 30090755)
17. Sawamura D, Li K, Chu ML, et al. Human bullous pemphigoid antigen (BPAG1). Amino acid sequences deduced from cloned cDNAs predict biologically important peptide segments and protein domains. J Biol Chem 1991; 266: 17784-90. (Pubitemid 21908010)
18. Hall RP III, Murray JC, McCord MM, et al. Rabbits immunized with a peptide encoded for by the 230-kD bullous pemphigoid antigen cDNA develop an enhanced inflammatory response to UVB irradiation: a potential animal model for bullous pemphigoid. J Invest Dermatol 1993; 101: 9-14. (Pubitemid 23213004)
19. Kiss M, Husz S, Janossy T, et al. Experimental bullous pemphigoid generated in mice with an antigenic epitope of the human hemidesmosomal protein BP230. J Autoimmun 2005; 24: 1-10. (Pubitemid 40269489)
20. Yoshida M, Hamada T, Amagai M, et al. Enzyme-linked immunosorbent assay using bacterial recombinant proteins of human BP230 as a diagnostic tool for bullous pemphigoid. J Dermatol Sci 2006; 41: 21-30. (Pubitemid 43075429)
21. Di Zenzo G, Thoma-Uszynski S, Fontao L, et al. Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid. Clin Immunol 2008; 128: 415-26.
22. Di Zenzo G, Thoma-Uszynski S, Calabresi V, et al. Demonstration of epitope-spreading phenomena in bullous pemphigoid: results of a prospective multicenter study. J Invest Dermatol 2011; 131: 2271-80.
23. Skaria M, Jaunin F, Hunziker T, et al. IgG autoantibodies from bullous pemphigoid patients recognize multiple antigenic reactive sites located predominantly within the B and C subdomains of the COOH-terminus of BP230. J Invest Dermatol 2000; 114: 998-1004. (Pubitemid 30252723)
24. Hamada T, Nagata Y, Tomita M, et al. Bullous pemphigoid sera react specifically with various domains of BP230, most frequently with C-terminal domain, by immunoblot analyses using bacterial recombinant proteins covering the entire molecule. Exp Dermatol 2001; 10: 256-63. (Pubitemid 32754994)
25. Kromminga A, Sitaru C, Hagel C, et al. Development of an ELISA for the detection of autoantibodies to BP230. Clin Immunol 2004; 111: 146-52. (Pubitemid 38482094)
26. Schmidt E, Zillikens D,. Modern diagnosis of autoimmune blistering skin diseases. Autoimmun Rev 2010; 10: 84-9.
27. Schmidt E, Dahnrich C, Rosemann A, et al. Novel ELISA systems for antibodies to desmoglein 1 and 3: correlation of disease activity with serum autoantibody levels in individual pemphigus patients. Exp Dermatol 2010; 19: 458-63.
28. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24. (Pubitemid 18091653)
29. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7. (Pubitemid 13221242)
30. Hochberg MC,. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
31. Sitaru C, Dahnrich C, Probst C, et al. Enzyme-linked immunosorbent assay using multimers of the 16th non-collagenous domain of the BP180 antigen for sensitive and specific detection of pemphigoid autoantibodies. Exp Dermatol 2007; 16: 770-7. (Pubitemid 47261869)
32. Altman DG,. Practical Statistics for Medical Research. London: Chapman & Hall, 1991.
33. Kobayashi M, Amagai M, Kuroda-Kinoshita K, et al. BP180 ELISA using bacterial recombinant NC16a protein as a diagnostic and monitoring tool for bullous pemphigoid. J Dermatol Sci 2002; 30: 224-32. (Pubitemid 35351315)
34. Zillikens D, Mascaro JM, Rose PA, et al. A highly sensitive enzyme-linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid. J Invest Dermatol 1997; 109: 679-83. (Pubitemid 27465925)
35. Sakuma-Oyama Y, Powell AM, Oyama N, et al. Evaluation of a BP180-NC16a enzyme-linked immunosorbent assay in the initial diagnosis of bullous pemphigoid. Br J Dermatol 2004; 151: 126-31. (Pubitemid 39061289)
36. Mariotti F, Grosso F, Terracina M, et al. Development of a novel ELISA system for detection of anti-BP180 IgG and characterization of autoantibody profile in bullous pemphigoid patients. Br J Dermatol 2004; 151: 1004-10. (Pubitemid 39573888)
37. Feng S, Lin L, Jin P, et al. Role of BP180NC16a-enzyme-linked immunosorbent assay (ELISA) in the diagnosis of bullous pemphigoid in China. Int J Dermatol 2008; 47: 24-8.
38. Roussel A, Benichou J, Randriamanantany ZA, et al. Enzyme-linked immunosorbent assay for the combination of bullous pemphigoid antigens 1 and 2 in the diagnosis of bullous pemphigoid. Arch Dermatol 2011; 147: 293-8.
39. Charneux J, Lorin J, Vitry F, et al. Usefulness of BP230 and BP180-NC16a enzyme-linked immunosorbent assays in the initial diagnosis of bullous pemphigoid: a retrospective study of 138 patients. Arch Dermatol 2011; 147: 286-91.
40. Amo Y, Ohkawa T, Tatsuta M, et al. Clinical significance of enzyme-linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid. J Dermatol Sci 2001; 26: 14-18. (Pubitemid 32372650)
41. Tampoia M, Lattanzi V, Zucano A, et al. Evaluation of a new ELISA assay for detection of BP230 autoantibodies in bullous pemphigoid. Ann N Y Acad Sci 2009; 1173: 15-20.
42. Wieland CN, Comfere NI, Gibson LE, et al. Anti-bullous pemphigoid 180 and 230 antibodies in a sample of unaffected subjects. Arch Dermatol 2010; 146: 21-5.